• DPPH as a Translational Antioxidant Benchmark

  2026-08-14

  DPPH is more than a color-changing reagent: it is a practical decision tool for ranking antioxidant capacity, comparing botanical sources, and designing orthogonal validation strategies. This article connects DPPH chemistry with the wild-versus-cultivated Taihangia rupestris study and outlines how translational teams can turn a rapid in vitro signal into a defensible discovery workflow.

• Angiotensin III: From RAAS Peptide to Assay Design

  2026-08-13

  Angiotensin III is more than a downstream RAAS metabolite: its cleavage-state biology can guide receptor, endocrine, cardiovascular, and emerging spike-binding assays. This article translates the 2025 angiotensin-peptide study into practical decisions for using the A1043 research reagent.

• Phosbind Biotin LC: PVDF Phosphoprotein Detection

  2026-08-13

  Phosbind Biotin LC (SKU F4004) is a phosphate-binding reagent for detecting phosphorylated proteins on PVDF membranes without relying on phospho-specific antibody sequence recognition. It is intended for Western Blot workflows using streptavidin-HRP and chemiluminescence, but it should not be used in aqueous-only protocols or stored long term as a working solution.

• Huangqin Decoction, AhR, and Stem Cell Repair

  2026-08-12

  Li et al. identify a microbiota–tryptophan metabolism–AhR–intestinal stem cell axis through which Huangqin decoction supports mucosal repair in a mouse model of ulcerative colitis. The study combines microbiome profiling, metabolite quantification, pathway measurements, and pharmacological and antibiotic perturbations to connect microbial metabolites with epithelial differentiation.

• CDCA–FXR–KLF11 Axis in Contrast AKI

  2026-08-12

  The reference study identifies an FXR–KLF11 transcriptional pathway through which Chenodeoxycholic Acid (CDCA) suppresses JAK2/STAT3 signaling and reduces contrast-induced acute kidney injury in preclinical models. Its value lies in connecting a bile acid receptor to a defined renal protective mechanism, while also highlighting the need for further dose, safety, and clinical validation.

• Dye Marking for Small Tissue Biopsies in Pathology

  2026-08-11

  The reference study evaluated whether common histological dyes could improve the visibility of very small biopsy fragments during routine tissue processing. Merbromin, hematoxylin, and Alcian blue improved observability, but hematoxylin offered the most practical balance because pathologists reported no interference with routine slide examination and lower toxicity than merbromin.

• Hoechst 33342/PI Double Staining Kit Guide

  2026-08-10

  The Hoechst 33342/PI Double Staining Kit (K2237) supports microscopy-based separation of normal, apoptotic, and necrotic cell populations by combining nuclear morphology with membrane-integrity readout. It is intended for scientific research workflows, not diagnostic or medical use, and should be interpreted with appropriate controls because late apoptosis and necrosis can produce overlapping fluorescence patterns.

• Erastin as a Ferroptosis Assay Benchmark

  2026-08-09

  Erastin is a ferroptosis inducer that helps researchers connect cystine deprivation, glutathione loss, lipid peroxidation, and GPX4-dependent cell injury. This guide presents an evidence-based assay framework that extends beyond cancer screening to improve interpretation of oxidative cell-death experiments.

• DHT at the Translational Edge of Cell State

  2026-08-08

  Dihydrotestosterone is more than an androgen receptor agonist: it is a controllable entry point for studying receptor-to-growth-factor signaling, disease phenotypes, and experimental cell-state transitions. This article connects DHT-driven EGFR and ERBB2 signaling with emerging insights into autophagy-linked meiotic initiation, while defining what is established, what remains exploratory, and how translational researchers can design more informative experiments.

• One-step TUNEL Cy5 Kit: TKI Resistance

  2026-08-07

  The One-step TUNEL Cy5 Apoptosis Detection Kit connects DNA-fragmentation readouts with mechanistic studies of TKI resistance. Learn how to interpret Cy5-TUNEL results in cultured cells and tissue sections without confusing apoptosis-associated signal with pathway identity.

• Sitagliptin Phosphate Monohydrate: DPP-4 Inhibitor Workflows

  2026-08-07

  Sitagliptin phosphate monohydrate from APExBIO empowers precise DPP-4 inhibition and incretin hormone studies, enabling robust metabolic and mechanosensory assays. Discover advanced workflows, troubleshooting insights, and the latest research-driven protocol enhancements for type II diabetes and metabolic disease models.

• Assessing Sulfamonomethoxine Toxicity in Aquatic Organisms

  2026-08-06

  This article synthesizes the findings of Huang et al., who systematically evaluated the acute and chronic toxicity of the veterinary sulfonamide antibiotic sulfamonomethoxine (SMM) across five aquatic species. Their results demonstrate marked sensitivity differences among trophic levels, highlighting microalgae as particularly vulnerable and emphasizing the need for careful monitoring of antibiotic residues in aquatic environments.

• Safe DNA Gel Stain: Sensitive DNA and RNA Visualization Rede

  2026-08-06

  Safe DNA Gel Stain from APExBIO sets a new standard for sensitive, biosafe nucleic acid detection in agarose and polyacrylamide gels. Its compatibility with blue-light excitation and streamlined workflows make it an ideal alternative to ethidium bromide, optimizing both safety and cloning efficiency for advanced molecular biology applications.

• Targeting Glutamine Metabolism in Hepatic Stellate Cells for

  2026-08-05

  The referenced study demonstrates that inhibiting glutamine metabolism in hepatic stellate cells (HSCs) alleviates liver fibrosis by downregulating GDH activity and reactivating mitochondrial sirtuin SIRT4. These insights identify a novel antifibrotic mechanism and suggest new directions for mitochondrial biogenesis research in chronic liver disease.

• Intravesical p21 mRNA-LNP: Localized Tumor Suppressor Therap

  2026-08-05

  This study pioneers the use of intravesical delivery of p21 mRNA-loaded lipid nanoparticles (LNPs) as a non-viral, localized tumor suppressor replacement strategy for bladder cancer. Results demonstrate robust restoration of p21, suppression of tumor growth, and a favorable safety profile, highlighting a promising direction for mRNA-based therapies targeting non-muscle-invasive disease.

451 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page